EPO Enlarged Board of Appeal issues G 2/21 decision

Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Pharma patent filings rise at EPO amid pandemic

5 April 2022 Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

Biotechnology

Compugen’s anti-PVRIG patent upheld by the EPO

18 July 2023 Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

More on this story

Europe

Pharma patent filings rise at EPO amid pandemic

5 April 2022 Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

Biotechnology

Compugen’s anti-PVRIG patent upheld by the EPO

18 July 2023 Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

More on this story

Europe

Pharma patent filings rise at EPO amid pandemic

5 April 2022 Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

Biotechnology

Compugen’s anti-PVRIG patent upheld by the EPO

18 July 2023 Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

EPO Enlarged Board of Appeal issues G 2/21 decision

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features